• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by SeaStar Medical Holding Corporation

    11/14/24 5:35:52 PM ET
    $ICU
    Medical/Dental Instruments
    Health Care
    Get the next $ICU alert in real time by email
    SC 13G 1 formsc13g.htm

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, DC 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

    (Amendment No. 0)*

     

    SEASTAR MEDICAL HOLDING CORPORATION

    (Name of Issuer)

     

    Common Stock, $0.0001 par value

    (Title of Class of Securities)

     

    81256L203

    (CUSIP Number)

     

    September 30, 2024

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

      ☒ Rule 13d-1(b)
         
      ☐ Rule 13d-1(c)
         
      ☐ Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934, as amended (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     
     

     

    CUSIP No. 81256L203

     

    1.

    NAME OF REPORTING PERSONS

    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

    Ayrton Capital LLC

     
    2.

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

     

     

    (a) ☐

    (b) ☒

    3.

    SEC USE ONLY

     

     
    4.

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

     

     

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON WITH

    5.

    SOLE VOTING POWER

     

    294,361*(1)

    6.

    SHARED VOTING POWER

     

    0

    7.

    SOLE DISPOSITIVE POWER

     

    294,361*(1)

    8.

    SHARED DISPOSITIVE POWER

     

    0

     

    9.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    294,361*(1)

     
    10.

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    (SEE INSTRUCTIONS)

     

    ☐

    11.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    6.6%(2)

     
    12.

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    IA

     

     

     
     

     

    CUSIP No. 81256L203

     

    1.

    NAME OF REPORTING PERSONS

    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

    Alto Opportunity Master Fund, SPC – Segregated Master Portfolio B

     
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

     

    (a) ☐

    (b) ☒

    3.

    SEC USE ONLY

     

     
    4.

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Cayman Islands

     

     

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON WITH

    5.

    SOLE VOTING POWER

     

    294,361*(1)

    6.

    SHARED VOTING POWER

     

    0

    7.

    SOLE DISPOSITIVE POWER

     

    294,361*(1)

    8.

    SHARED DISPOSITIVE POWER

     

    0

     

    9.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    294,361*(1)

     
    10.

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    (SEE INSTRUCTIONS)

     

    ☐

    11.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    6.6%(2)

     
    12.

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    CO

     

     

     
     

     

    CUSIP No. 81256L203

     

    1.

    NAME OF REPORTING PERSONS

    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

    Waqas Khatri

     
    2.

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

     

     

    (a) ☐

    (b) ☒

    3.

    SEC USE ONLY

     

     
    4.

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    United States

     

     

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON WITH

    5.

    SOLE VOTING POWER

     

    294,361*(1)

    6.

    SHARED VOTING POWER

     

    0

    7.

    SOLE DISPOSITIVE POWER

     

    294,361*(1)

    8.

    SHARED DISPOSITIVE POWER

     

    0

     

    9.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    294,361*(1)

     
    10.

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    (SEE INSTRUCTIONS)

     

    ☐

    11.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    6.6%(2)

     
    12.

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    IN

     

     

     
     

     

    CUSIP No. 81256L203

     

    Item 1. (a). Name of Issuer:
         
        Seastar Medical Holding Corporation
         
      (b). Address of issuer’s principal executive offices:
         
        3513 Brighton Blvd., Suite 410
        Denver, CO 80216
         
         
    Item 2. (a). Name of person filing:
         
        Ayrton Capital LLC
        Alto Opportunity Master Fund, SPC – Segregated Master Portfolio B
        Waqas Khatri
         
        Address or principal business office or, if none, residence:
         
      (b). Ayrton Capital, LLC
        55 Post Rd West, 2nd Floor
        Westport, CT 06880
         
        Alto Opportunity Master Fund, SPC – Segregated Master Portfolio B
        Suite #7, Grand Pavilion Commercial Centre
        802 West Bay Road
        Grand Cayman
        P.O. Box 10250
        Cayman Islands
         
        Waqas Khatri
        55 Post Rd West, 2nd Floor
        Westport, CT 06880
         
      (c). Citizenship:
         
        Ayrton Capital LLC – Delaware
        Alto Opportunity Master Fund, SPC – Segregated Master Portfolio B – Cayman Islands
        Waqas Khatri – United States
         
      (d). Title of class of securities:
         
        Common Stock, $0.0001 par value
         
      (e). CUSIP No.:
         
        81256L203

     

     
     

     

    CUSIP No. 81256L203

     

    Item 3. If This Statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b), or (c), check whether the person filing is a:
       
      Ayrton Capital LLC

     

      (a) ☐ Broker or Dealer Registered Under Section 15 of the Act (15 U.S.C. 78o)
      (b) ☐ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c)
      (c) ☐ Insurance Company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c)
      (d) ☐ Investment Company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8)
      (e) ☒ Investment Adviser in accordance with § 240.13d-1(b)(1)(ii)(E)
      (f) ☐ Employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F)
      (g) ☐ Parent Holding Company or control person in accordance with § 240.13d-1(b)(ii)(G)
      (h) ☐ Savings Association as defined in § 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813)
      (i) ☐ Church plan that is excluded from the definition of an investment company under § 3(c)(15) of the Investment Company Act of 1940 (15 U.S.C. 80a-3)
      (j) ☐ A non-U.S. institution in accordance with § 240.13d-1(b)(ii)(J)
      (k) ☐ Group, in accordance with § 240.13d-1(b)(ii)(K). If filing as a non-U.S. institution in accordance with § 240.13d–1(b)(1)(ii)(J), please specify the type of institution: ________

     

    Item 4. Ownership.
       
      Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

     

      (a) Amount beneficially owned:
         
        Ayrton Capital LLC – 294,361*(1)
        Alto Opportunity Master Fund, SPC – Segregated Master Portfolio B – 294,361*(1)
        Waqas Khatri – 294,361*(1)
         
      (b) Percent of class:
         
        Ayrton Capital LLC – 6.6%(2)
        Alto Opportunity Master Fund, SPC – Segregated Master Portfolio B – 6.6%(2)
        Waqas Khatri – 6.6%(2)
         
      (c) Number of shares as to which Ayrton Capital LLC has:

     

      (i) Sole power to vote or to direct the vote    294,361*(1) ,
               
      (ii) Shared power to vote or to direct the vote   0 ,
               
      (iii) Sole power to dispose or to direct the disposition of    294,361*(1) ,
               
      (iv) Shared power to dispose or to direct the disposition of   0 .
               
      Number of shares as to which Alto Opportunity Master Fund SPC – Segregated Master Portfolio B has:     ,
               
      (i) Sole power to vote or to direct the vote    294,361*(1) ,
               
      (ii) Shared power to vote or to direct the vote   0 ,
               
      (iii) Sole power to dispose or to direct the disposition of    294,361*(1) ,
               
      (iv) Shared power to dispose or to direct the disposition of   0 .
               
      Number of shares as to which Waqas Khatri has:      
             
      (i) Sole power to vote or to direct the vote    294,361*(1) ,
               
      (ii) Shared power to vote or to direct the vote   0 ,
               
      (iii) Sole power to dispose or to direct the disposition of    294,361*(1) ,
               
      (iv) Shared power to dispose or to direct the disposition of   0 .

     

    *Shares reported herein represent Common Stock of Seastar Medical Holding Corporation (the “Issuer”) held by Alto Opportunity Master Fund, SPC – Segregated Master Portfolio B, a Cayman Islands exempted company (the “Fund”). The Fund is a private investment vehicle for which Ayrton Capital LLC, a Delaware limited liability company (the “Investment Manager”), serves as the investment manager. Waqas Khatri serves as the managing member of the Investment Manager (all of the foregoing, collectively, the “Reporting Persons”).

     

     
     

     

    CUSIP No. 81256L203

     

    (1) Represents 294,361 shares of Common Stock issuable on the exercise of certain warrants (the “Warrants”) held by the Reporting Persons. The issuable shares of Common Stock related to the exercise of the Warrants are subject to a 9.99% beneficial ownership blocker.

     

    (2) Based on (i) 4,191,783 shares of Common Stock of the Issuer that were outstanding as of August 18, 2024; and (ii) 294,361 shares of Common Shares issuable on the exercise of the Warrants held by the Reporting Persons. The amount of shares outstanding was based upon a statement in the Issuer’s Form 424B5, filed on August 21, 2024.

     

    For the sake of clarity, the holdings of the Reporting Persons reported herein are as of September 30, 2024.

     

    By virtue of these relationships (i.e., Mr. Khatri’s sole authority to direct the affairs of the Investment Manager, including the voting and disposition of shares of Common Shares held by all Reporting Persons), the Reporting Persons may be deemed to have sole voting and dispositive power with respect to the shares owned directly by the Fund. This report shall not be deemed an admission that the Reporting Persons are beneficial owners of the shares for purposes of Section 13 of the Act, or for any other purpose. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of the Reporting Person’s pecuniary interest therein.

     

    Item 5. Ownership of Five Percent or Less of a Class.
       
      If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ☐.
       
    Item 6. Ownership of More Than Five Percent on Behalf of Another Person.
       
      If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.
       
      Not applicable

     

     
     

     

    CUSIP No. 81256L203

     

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
       
      If a parent holding company or control person has filed this schedule, pursuant to Rule 13d-1(b)(1)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company or control person has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.
       
      Not applicable
       
     Item 8. Identification and Classification of Members of the Group.
       
      If a group has filed this schedule pursuant to § 240.13d-1(b)(1)(ii)(J), so indicate under Item 3(j) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to Rule 13d- 1(c) or Rule 13d-1(d), attach an exhibit stating the identity of each member of the group.
       
      Not applicable
       
    Item 9. Notice of Dissolution of Group.
       
      Notice of dissolution of a group may be furnished as an exhibit stating the date of the dissolution and that all further filings with respect to transactions in the security reported on will be filed, if required, by members of the group, in their individual capacity. See Item 5.
       
      Not applicable
       
    Item 10. Certification.
       
      By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

     

     
     

     

    CUSIP No. 81256L203

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: November 14, 2024 Ayrton Capital LLC
         
      By: /s/ Waqas Khatri
      Name: Waqas Khatri
      Title: Managing Member
         
      Alto Opportunity Master Fund, SPC – Segregated Master Portfolio B
         
      By: /s/ Waqas Khatri
      Name: Waqas Khatri
      Title: Managing Member of Ayrton Capital LLC
         
      Waqas Khatri
         
      By: /s/ Waqas Khatri

     

    The original statement shall be signed by each person on whose behalf the statement is filed or his authorized representative. If the statement is signed on behalf of a person by his authorized representative other than an executive officer or general partner of the filing person, evidence of the representative’s authority to sign on behalf of such person shall be filed with the statement, provided, however, that a power of attorney for this purpose which is already on file with the Commission may be incorporated by reference. The name and any title of each person who signs the statement shall be typed or printed beneath his signature.

     

    Note. Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See § 240.13d-7 for other parties for whom copies are to be sent.

     

    Attention. Intentional misstatements or omissions of fact constitute Federal criminal violations (see § 18 U.S.C. 1001).

     

     
     

     

    CUSIP No. 81256L203

     

    Exhibit 1

     

    Joint Filing Statement

     

    Statement Pursuant to Rule 13d-1(k)(1)

     

    The undersigned hereby consent and agree to file a joint statement on Schedule 13G under the Securities Exchange Act of 1934, as amended, with respect to the Common Stock, $0.0001 par value, of Seastar Medical Holding Corporation, beneficially owned by them, together with any or all amendments thereto, when and if appropriate. The parties hereto further consent and agree to file this Statement pursuant to Rule 13d-1(k)(1)(iii) as an exhibit to Schedule 13G, thereby incorporating the same into such Schedule 13G.

     

    Dated: November 14, 2024 Ayrton Capital LLC
         
      By: /s/ Waqas Khatri
      Name: Waqas Khatri
      Title: Managing Member
         
      Alto Opportunity Master Fund, SPC – Segregated Master Portfolio B
         
      By: /s/ Waqas Khatri
      Name: Waqas Khatri
      Title: Managing Member of Ayrton Capital LLC
         
      Waqas Khatri
       
      By: /s/ Waqas Khatri

     

     

    Get the next $ICU alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ICU

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $ICU
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by SeaStar Medical Holding Corporation

      SC 13G - SeaStar Medical Holding Corp (0001831868) (Subject)

      11/14/24 5:35:52 PM ET
      $ICU
      Medical/Dental Instruments
      Health Care

    $ICU
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Chief Medical Officer Chung Kevin

      4 - SeaStar Medical Holding Corp (0001831868) (Issuer)

      4/3/25 7:33:39 PM ET
      $ICU
      Medical/Dental Instruments
      Health Care
    • SEC Form 4 filed by Chief Financial Officer Green David A

      4 - SeaStar Medical Holding Corp (0001831868) (Issuer)

      4/3/25 7:33:07 PM ET
      $ICU
      Medical/Dental Instruments
      Health Care
    • Director Neuman John bought $153,227 worth of shares (40,000 units at $3.83) (SEC Form 4)

      4 - SeaStar Medical Holding Corp (0001831868) (Issuer)

      2/27/25 3:51:55 PM ET
      $ICU
      Medical/Dental Instruments
      Health Care

    $ICU
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Neuman John bought $153,227 worth of shares (40,000 units at $3.83) (SEC Form 4)

      4 - SeaStar Medical Holding Corp (0001831868) (Issuer)

      2/27/25 3:51:55 PM ET
      $ICU
      Medical/Dental Instruments
      Health Care
    • Chief Medical Officer Chung Kevin bought $8,458 worth of shares (4,250 units at $1.99), increasing direct ownership by 45% to 13,685 units (SEC Form 4)

      4 - SeaStar Medical Holding Corp (0001831868) (Issuer)

      11/19/24 5:18:50 PM ET
      $ICU
      Medical/Dental Instruments
      Health Care
    • Chief Medical Officer Chung Kevin bought $4,258 worth of shares (1,000 units at $4.26), increasing direct ownership by 12% to 9,435 units (SEC Form 4)

      4 - SeaStar Medical Holding Corp (0001831868) (Issuer)

      10/1/24 4:47:46 PM ET
      $ICU
      Medical/Dental Instruments
      Health Care

    $ICU
    Financials

    Live finance-specific insights

    See more
    • SeaStar Medical to Report First Quarter Financial Results on May 14, 2025

      DENVER, May 07, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (NASDAQ:ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life, announced today that it will report its first quarter financial results after market close on Wednesday, May 14, 2025, and host a webcast and conference call to discuss its financial results and business progress. Date/Time:Wednesday, May 14, 2025, at 4:30 p.m. ET / 2:30 p.m. MTWebcast:The live webcast and replay can be found here.Conference ID:2078693Dial-in numbers:1 (800) 715-9871 within the U.S. 1 (646) 307-1963 from outside the U.S.   A rep

      5/7/25 10:00:00 AM ET
      $ICU
      Medical/Dental Instruments
      Health Care
    • SeaStar Medical Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates

      DENVER, March 27, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (NASDAQ:ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life announced today financial results for the three months and year ended December 31, 2024, and provided business updates on key initiatives. "Our significant accomplishment in 2024 position us well for a transformational year in 2025," said Eric Schlorff, SeaStar Medical CEO. "Last year, we not only received our first product approval for QUELIMMUNE and began our commercial launch, but we added 14 new clinical sites for our NEUTRALIZE AKI pivotal clinic

      3/27/25 4:05:00 PM ET
      $ICU
      Medical/Dental Instruments
      Health Care
    • SeaStar Medical to Report Fourth Quarter and Year-End 2024 Financial Results on March 27, 2025

      DENVER, March 24, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (NASDAQ:ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life, announced today that it will report its fourth quarter and year-end 2024 financial results after market close on Thursday, March 27, 2025, and host a webcast and conference call to discuss its financial results and business progress. Date/Time:Thursday, March 27, at 4:30 p.m. ET / 1:30 p.m. PT  Webcast:The live webcast and replay can be found here.  Conference ID:2078693  Dial-in numbers:1 (800) 715-9871 within the U.S.   1 (646) 307-1963 from outside

      3/24/25 5:30:00 PM ET
      $ICU
      Medical/Dental Instruments
      Health Care

    $ICU
    SEC Filings

    See more
    • SEC Form DEF 14A filed by SeaStar Medical Holding Corporation

      DEF 14A - SeaStar Medical Holding Corp (0001831868) (Filer)

      5/7/25 9:05:41 AM ET
      $ICU
      Medical/Dental Instruments
      Health Care
    • SEC Form DEFA14A filed by SeaStar Medical Holding Corporation

      DEFA14A - SeaStar Medical Holding Corp (0001831868) (Filer)

      5/6/25 5:26:23 PM ET
      $ICU
      Medical/Dental Instruments
      Health Care
    • SEC Form EFFECT filed by SeaStar Medical Holding Corporation

      EFFECT - SeaStar Medical Holding Corp (0001831868) (Filer)

      4/30/25 12:15:20 AM ET
      $ICU
      Medical/Dental Instruments
      Health Care

    $ICU
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • SeaStar Medical to Report First Quarter Financial Results on May 14, 2025

      DENVER, May 07, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (NASDAQ:ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life, announced today that it will report its first quarter financial results after market close on Wednesday, May 14, 2025, and host a webcast and conference call to discuss its financial results and business progress. Date/Time:Wednesday, May 14, 2025, at 4:30 p.m. ET / 2:30 p.m. MTWebcast:The live webcast and replay can be found here.Conference ID:2078693Dial-in numbers:1 (800) 715-9871 within the U.S. 1 (646) 307-1963 from outside the U.S.   A rep

      5/7/25 10:00:00 AM ET
      $ICU
      Medical/Dental Instruments
      Health Care
    • SeaStar Medical Announces CEO Interview on Benzinga All Access to Occur Today at Approximately 10:50 am Eastern Time

      DENVER, April 30, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (NASDAQ:ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life announced today that Eric Schlorff, CEO of SeaStar Medical, will be a featured guest today, Wednesday, April 30th, at approximately 10:50 am Eastern Time on the Benzinga All Access Show. The event will be broadcast live and can be viewed at https://youtube.com/live/ki1hFktn_2Y?feature=share. An archived recording of the presentation will be available on the investor relations section of the Sea Star Medical's website on the Events and Presentations pa

      4/30/25 8:05:00 AM ET
      $ICU
      Medical/Dental Instruments
      Health Care
    • FDA Grants SeaStar Medical Two New Breakthrough Device Designations for SCD Therapy to Treat Systemic Inflammatory Response in Adult and Pediatric Patients Undergoing Cardiac Surgery

      DENVER, April 08, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (NASDAQ:ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life, announced today that the U.S. Food and Drug Administration (FDA) has granted SeaStar Medical two new Breakthrough Device Designations for its Selective Cytopheretic Device (SCD) therapy. The two new Breakthrough Device Designations are indicated for the treatment of systemic inflammatory response in 1) adult patients undergoing cardiac surgery and 2) pediatric patients undergoing cardiac surgery towards prevention of post-operative adverse complicatio

      4/8/25 8:05:00 AM ET
      $ICU
      Medical/Dental Instruments
      Health Care